Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity

Feng Zhang, Suo Pan, Guanhua Hu, Lu Bai, Yingxi Zuo, Zhengli Xu, Lanping Xu, Yu Wang, Xiaohui Zhang, Xiaojun Huang, Yifei CHENG

Blood (2025) 146 (Supplement 1): 5977.

https://doi.org/10.1182/blood-2025-5977

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Transient hepatic reconstitution of thymic factors using mRNA rejuvenates T cell immunity, and improves vaccination and cancer immunotherapy responses in aged hosts

Mirco Friedrich, Julie Pham, Jiakun Tian, Hongyu Chen, Jiahao Huang, Niklas Kehl, Sophia Liu, Blake Lash, Fei Chen, Xiao Wang, Rhiannon Macrae, Feng Zhang

Blood (2025) 146 (Supplement 1): 380.

https://doi.org/10.1182/blood-2025-380

Published: 2025

Journal Articles

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Jian Huang, Rumeng Li, Tiejun Gong, Pengxiang Guo, Lihong Shou, Hu Zhu, Zongjiu Jiao, Feng Zhang, Qingchi Liu, Lidong Zhao, Guocai Wu, Lili Chen, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2025-5530

Published: 2025

Journal Articles

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Lihong Shou, Qingchi Liu, Feng Zhang, Cuicui WU, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2024) 144 (Supplement 1): 3180.

https://doi.org/10.1182/blood-2024-210330

Published: 2024

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Qianru Zhang, Wenqiang Yan, Lu Sun, Guoqing Han, Qiaoli Wu, Yiran Cui, Bolin Liu, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Lugui Qiu, Qingguo Li, Gang An, Yuxuan Liu

Blood (2024) 144 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2024-202680

Published: 2024

Journal Articles

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Hu Zhou, Xuewen Song, Zengmei Sheng, Feng Zhang, Guocai Wu, Lidong Zhao, ZePing Zhou, Lihong Shou, Lili Chen, Xiaotao Wang, Jian Huang, Rong Fu, Dan Chen, Ruibin Huang, Zongjiu Jiao, Jian Lu, Yajun Ruan, Yu Jiao

Blood (2024) 144 (Supplement 1): 5406.

https://doi.org/10.1182/blood-2024-200074

Published: 2024

Journal Articles

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rahul S. Vedula, Hannah Q. Karp, Jeremy Koob, Felicia Lim, Jacqueline S. Garcia, Eric S. Winer, Marlise R. Luskin, Gabriel Ghiaur, Annette S. Kim, Lan W. Beppu, Olga Sala-Torra, Jerald Radich, Jonathan Gootenberg, Omar Abudayyeh, Feng Zhang, R. Coleman Lindsley

Blood (2024) 144 (12): 1290–1299.

https://doi.org/10.1182/blood.2023022908

Published: 2024

Includes: Supplemental data

Journal Articles

Rational Engineering of Minimally Immunogenic Nucleases for Gene Therapy

Rumya Raghavan, Mirco Friedrich, Indigo King, Michael Killian, Michael Platten, Rhiannon Macrae, Yifan Song, Lucas Nivon, Feng Zhang

Blood (2023) 142 (Supplement 1): 7126.

https://doi.org/10.1182/blood-2023-180987

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

Blood (2021) 138 (Supplement 1): 387.

https://doi.org/10.1182/blood-2021-145664

Published: 2021

Journal Articles

IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis

Blood (2021) 137 (7): 945–958.

https://doi.org/10.1182/blood.2020007075

Published: 2021

Includes: Supplemental data

Journal Articles

Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ

Lei Zhang, Jing Li, Hui Xu, Xianyu Shao, Li Fu, Ye Hou, Caiqing Hao, Wenyan Li, Kanak Joshi, Wei Wei, Yan Xu, Feng Zhang, Shaojun Dai, Peter Breslin, Jiwang Zhang, Jun Zhang

Blood (2020) 135 (14): 1133–1145.

https://doi.org/10.1182/blood.2019001863

Published: 2020

Includes: Supplemental data

Journal Articles

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Lei Zhang, PhD, Huacheng Luo, PhD, Jing Li, Hong-Min Ni, Mark Sellin, Feng Zhang, Jun Zhang, Peter Breslin, PhD, Wei Wei, William Small, Jr., Wen-Xin Ding, Suming Huang, PhD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 3714.

https://doi.org/10.1182/blood-2019-131332

Published: 2019

Journal Articles

Biology and Application of Genome Editing

Feng Zhang

Blood (2019) 134 (Supplement_1): SCI-22.

https://doi.org/10.1182/blood-2019-121282

Published: 2019

Journal Articles

Precision Assessment of on- and Off-Target Effects of mTOR Kinase Inhibitors in a Mouse Model

Cuiqing Fan, PhD, Xiongwei Cai, PhD, Feng Zhang, PhDcandidate, Cindy Hochstetler, PhDcandidate, Xiaoyi Chen, PhD, Fukun Guo, PhD, Weidong Tian, PhD, Yi Zheng, PhD

Blood (2018) 132 (Supplement 1): 2632.

https://doi.org/10.1182/blood-2018-99-115225

Published: 2018

Journal Articles

mTOR Restricts Chromatin Access and Genomic Activity to Maintain Hematopoietic Stem Cell Quiescence and Engraftment

Cuiqing Fan, PhD, Chuntao Zhao, PhD, Feng Zhang, Xiongwei Cai, PhD, Lingli Xu, Shan Lin, PhD, Xiaoyi Chen, PhD, Fukun Guo, PhD, Richard Q Lu, PhD, Weidong Tian, PhD, Yi Zheng, PhD

Blood (2017) 130 (Supplement 1): 2416.

https://doi.org/10.1182/blood.V130.Suppl_1.2416.2416

Published: 2017

Journal Articles

Crispr-Cas9 Saturating Mutagenesis Reveals an Achilles Heel in the BCL11A Erythroid Enhancer for Fetal Hemoglobin Induction (by Genome Editing)

Blood (2015) 126 (23): 638.

https://doi.org/10.1182/blood.V126.23.638.638

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Transient hepatic reconstitution of thymic factors using mRNA rejuvenates T cell immunity, and improves vaccination and cancer immunotherapy responses in aged hosts

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias

Rational Engineering of Minimally Immunogenic Nucleases for Gene Therapy

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis

Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Biology and Application of Genome Editing

Precision Assessment of on- and Off-Target Effects of mTOR Kinase Inhibitors in a Mouse Model

mTOR Restricts Chromatin Access and Genomic Activity to Maintain Hematopoietic Stem Cell Quiescence and Engraftment

Crispr-Cas9 Saturating Mutagenesis Reveals an Achilles Heel in the BCL11A Erythroid Enhancer for Fetal Hemoglobin Induction (by Genome Editing)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only